scholarly journals Exit Strategy from COVID-19: Vaccination and an Alternative Solution 

2021 ◽  
Author(s):  
Indrani Roy
Keyword(s):  
Side Effects ◽  
Mass Vaccination ◽  
Vested Interest ◽  
Alternative Solution ◽  
Sufficient Data ◽  
Exit Strategy ◽  
Good Science ◽  
The Uk

Vaccination groups all over the globe made a strong coordinated effort to put an end to the current COVID-19 crisis. Since vaccination started first in the UK on 8 th December, 2020 we have sufficient data to analyse and derive useful results. It addressed issues viz. seasonality, indirect consequences of mass vaccination and fast mutation of the virus after mass vaccination. To develop useful timely insights, some similarities between COVID-19 and Flu received attention. Critical and open analyses, balanced discussion in the current crucial stage are desperately needed. Questioning, debating and criticism are always the basis of good science and the main pillars to its advancement. With that objective in mind, it is an effort to explore areas relating to the effectiveness of COVID-19 vaccines with a pragmatic viewpoint. Policymakers will be greatly benefitted from such analyses. An alternative optimistic pathway is also mentioned which was proposed as early as 17 th March, 2020 and is practically without side effects and no vested interest involved.

scholarly journals Exit strategy of COVID-19 crisis and pathways of Vaccination

2022 ◽  
Author(s):  
Indrani Roy
Keyword(s):  
Dominant Role ◽  
Health And Safety ◽  
Mass Vaccination ◽  
Exit Strategy ◽  
Current Crisis ◽  
Common People ◽  
Safety Issues ◽  
Seasonal Flu ◽  
The Uk ◽  
Almost All

There is a strong coordinated effort by vaccination groups all over the world to put an end to the current crisis of COVID-19. The Mass vaccination first started in the UK on 8th December 2020 and soon afterward covered all of the globe. Now sufficient data are available to analyse and compare some results to explore many aftereffects of vaccination. Some influence variables on transmissions of the disease were discussed e.g., mass vaccination, lockdown and seasonality. To address seasonality, similarities between COVID-19 and seasonal Flu are discussed to gain useful insight. Like Flu, seasonality was shown to play a dominant role in transmissions of COVID-19 in the Eu-rope and US. In terms of mass vaccination, adverse reactions after vaccination received attention, as health and safety issues of the general public are of prime importance. Apart from direct side effects, the secondary effect of mass vaccination needs attention too. After the initiation of vaccination programme , almost all countries experienced a sudden surge of transmission and most countries had to impose strict lockdown measures. Many countries, those showed a low prevalence of the disease, suddenly showed a steep jump after the onset of mass vaccination. Some countries even followed a synchronized pattern between the rate of transmissions and the variation of vaccine doses; the pattern seemed distinct with the sudden steep rise/fall in vaccine doses (e.g., countries India, Indonesia among others). In that context, fast mutation of the virus and new variants after mass vaccination and possible mechanisms/consequences were discussed. Balanced discussion, critical and open analyses are desperately needed in the current crucial stage. Debating, questioning and criticism are always the foundation of good science and the main pillars to its progress. Following that objective, it is an effort to explore pragmatically, areas relating to the effectiveness of the COVID-19 vaccine and the exit strategy via the pathway of vaccination. Policymakers, academics, patients and common people will be greatly benefitted from such critical, transparent and balanced analyses.

Sleep and epilepsy—chicken or egg?

2018 ◽  
Author(s):  
Dora A. Lozsadi
Keyword(s):  
Side Effects ◽  
Sleep Disorders ◽  
Learning Disability ◽  
Excessive Daytime Sleepiness ◽  
Daytime Sleepiness ◽  
Seizure Control ◽  
Subjective Sleep ◽  
Neurological Conditions ◽  
The Uk ◽  
Patients With Epilepsy

Epilepsy is the commonest serious chronic neurological condition, affecting 0.5% of the population in the UK. Subjective sleep disturbance and excessive daytime sleepiness are reported to be 50% more frequent in those with epilepsy than in controls. Causes are multiple. Both poor seizure control and nocturnal attacks are known to contribute to such sleep disorders. Epilepsy also increases the risk of associated sleep disorders, and additional neurological conditions, such as dementia, learning disability, and depression. These all affect sleep hygiene. Prescribed anti-epileptic drugs will further aggravate the problem. Side-effects will include drowsiness. Sedating benzodiazepines and barbiturates are considered worst offenders. Others affect sleep architecture to varying degrees and/or cause insomnia. While hyper-somnolence in patients with epilepsy will raise the possibility of any of the above issues, sleep deprivation is one of the commonest seizure triggers. This chapter will shed more light on the intricate relationship between sleep and epilepsy.

Dopamine agonists for parkinson’s disease

1991 ◽  
Vol 29 (2) ◽  
pp. 7-8
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Therapeutic Efficacy ◽  
Dopamine Agonists ◽  
Dopa Decarboxylase ◽  
Decarboxylase Inhibitor ◽  
Duration Of Action ◽  
Motor Disability ◽  
The Uk

Bromocriptine, lysuride (formerly lisuride, Revanil – Roche) and pergolide (not yet marketed in the UK) are dopamine agonists developed for use in the treatment of patients with Parkinson’s disease. Combination of a dopamine agonist with levodopa plus a dopa-decarboxylase inhibitor (‘co-dieldopa’)* may have advantages at all stages of the disease. The aim of combined co-dieldopa + agonist treatment is to limit some of the problems with prolonged co-dieldopa use alone; especially fluctuations in motor disability.1 It is still not clear how the three agonists compare with each other for therapeutic efficacy, duration of action, and side effects, nor how they are best combined with co-dieldopa.

scholarly journals Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in England

2021 ◽  
Author(s):  
Nikos Evangelou ◽  
Afagh Garjani ◽  
Sameer Patel ◽  
Dhiren Bharkhada ◽  
Waqar Rashid ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
General Population ◽  
Mass Vaccination ◽  
Test Results ◽  
Health Security ◽  
Disease Modifying Therapies ◽  
Multiple Sclerosis Population ◽  
Impaired Immune Response ◽  
Disease Modifying ◽  
The Uk

Abstract This study aimed to understand changes in the risk of SARS-CoV-2 infection among all people with multiple sclerosis (MS) receiving immunomodulatory disease-modifying therapies (DMTs) in England, compared to the general population, following mass vaccination. Longitudinal data collected by the National Health Service (NHS) England on all MS DMT prescriptions and the UK Health Security Agency on all registered SARS-CoV-2 test results were analysed. The incidence rate ratio of SARS-CoV-2 infection among people with MS taking DMTs compared to the general population was calculated before (November 2020-January 2021) and after (July-August 2021) mass vaccination. Risk of SARS-CoV-2 infection among people on ocrelizumab or fingolimod compared to the general population increased following liberalisation of COVID-19 restrictions (during March-July 2021) despite mass vaccination. No changes were found with other DMTs. These findings converge with the impaired immune response to vaccines observed with ocrelizumab and fingolimod.

Two Doses of MMR Vaccine—Sufficient to Eradicate Measles, Mumps and Rubella?

1988 ◽  
Vol 16 (3) ◽  
pp. 129-135 ◽  
Author(s):  
Karin Fahlgren
Keyword(s):  
Young Adults ◽  
Side Effects ◽  
Vaccination Programme ◽  
Mass Vaccination ◽  
Crucial Importance ◽  
Mmr Vaccine ◽  
Virus Strains

A review has been done of the available literature on measles, mumps, rubella and vaccines against these diseases. So far, 17 studies on the same virus strains as those in M-M-R II have been published. The rate of seroconversion is practically 100% for rubella, generally more than 90% for measles and between 40 and 100% for mumps. Immediate side effects of vaccinaton are mild in infants and negligible in schoolchildren. However, the follow-up periods are short. In the only 10-year follow-up published, 14 subjects remained at the end of the period, and the vaccine studied differed from M-M-R II. Large, well-documented studies of MMR vaccination in unselected populations are rare. It must be of crucial importance that the immunity situation is followed up continuously for both vaccinated and non-vaccinated individuals when a mass vaccination programme has been introduced as there will be a risk of outbreaks of diseases mostly among young adults.

scholarly journals The effectiveness of social bubbles as part of a Covid-19 lockdown exit strategy, a modelling study

2020 ◽  
Author(s):  
Trystan Leng ◽  
Connor White ◽  
Joe Hilton ◽  
Adam Kucharski ◽  
Lorenzo Pellis ◽  
...  
Keyword(s):  
Reproduction Number ◽  
Base Case ◽  
Exit Strategy ◽  
Epidemic Threshold ◽  
Case Scenario ◽  
Base Case Scenario ◽  
The Social ◽  
The Uk ◽  
The Impact ◽  
Epidemic Risk

AbstractBackgroundDuring the Covid-19 lockdown, contact clustering in social bubbles may allow extending contacts beyond the household at minimal additional risk and hence has been considered as part of modified lockdown policy or a gradual lockdown exit strategy. We estimated the impact of such strategies on epidemic and mortality risk using the UK as a case study.MethodsWe used an individual based model for a synthetic population similar to the UK, that is stratified into transmission risks from the community, within the household and from other households in the same social bubble. The base case considers a situation where non-essential shops and schools are closed, the secondary household attack rate is 20% and the initial reproduction number is 0.8. We simulate a number of strategies including variations of social bubbles, i.e. the forming of exclusive pairs of households, for particular subsets of households (households including children and single occupancy households), as well as for all households. We test the sensitivity of the results to a range of alternative model assumptions and parameters.ResultsClustering contacts outside the household into exclusive social bubbles is an effective strategy of increasing contacts while limiting some of the associated increase in epidemic risk. In the base case scenario social bubbles reduced cases and fatalities by 17% compared to an unclustered increase of contacts. We find that if all households were to form social bubbles the reproduction number would likely increase to 1.1 and therefore beyond the epidemic threshold of one. However, strategies that allow households with young children or single occupancy households to form social bubbles only increased the reproduction number by less than 10%. The corresponding increase in morbidity and mortality is proportional to the increase in the epidemic risk but is largely focussed in older adults independently of whether these are included in the social bubbles.ConclusionsSocial bubbles can be an effective way of extending contacts beyond the household limiting the increase in epidemic risk, if managed appropriately.

scholarly journals Oncology and palliative care

2019 ◽  
pp. 125-208
Keyword(s):  
Palliative Care ◽  
Side Effects ◽  
Life Expectancy ◽  
Industrialized Countries ◽  
Normal Tissues ◽  
Body Tissues ◽  
Biological Treatments ◽  
The Common ◽  
Oncology Practice ◽  
The Uk

This chapter provides an overview of current oncology practice as it pertains to palliative care. It covers the care of patients undergoing oncological interventions including some of the newer biological treatments and includes the management of the common side effects associated with the management of solid tumours in adults. It includes a succinct summary of the current management of common cancers. Cancer is an important cause of morbidity and mortality, particularly in industrialized countries. Currently in the UK, one person in two will be diagnosed with some form of cancer during their lifetime and one in four will die of the disease. Cancer incidence increases exponentially with age; with increasing life expectancy, cancer will become an even more common problem in the future. Cancers may develop in all body tissues. The chapter reviews the various ways that the cells that form cancers can be differentiated from cells in normal tissues.

scholarly journals Introducing an Innovative Oral Neuromuscular Treatment of the Underlying Reason for Reflux Caused by Hiatus Hernia: An Aggravating Factor in Esophagitis

2021 ◽  
Author(s):  
Mary Hägg ◽  
Thomas Franzén
Keyword(s):  
Side Effects ◽  
Hiatal Hernia ◽  
Medical Device ◽  
Hiatus Hernia ◽  
Surgical Interventions ◽  
Chest Cavity ◽  
Negative Side ◽  
Root Cause ◽  
Negative Side Effects ◽  
The Uk

Esophagitis is a debilitating disease often leading to more serious conditions. It is aggravated by refluxed stomach acids for which the usual treatment is PPI drugs that at best treat the symptoms, not the underlying cause of reflux. Surgical interventions address the root - Hiatal muscular incompetence - but are invasive and expensive. Both treatments have proven unwanted side-effects. Neuromuscular treatment is a new and innovative alternative that addresses the root cause of reflux. The science and evidence behind this treatment is presented here. Reflux cannot happen when the diaphragm functions properly and maintains adequate pressure in the Hiatal canal, otherwise the neck of the stomach can intrude through the diaphragm into the chest cavity allowing reflux and conditions such as GERD, LPR, silent reflux, dyspepsia and more. This is especially common at night, when in bed. Training with a simple and inexpensive neuromuscular medical device takes 90 seconds per day, self-administered by the patient without medication or surgical intervention. No negative side effects are recorded for this treatment. Currently, 40 000 individuals have treated with the device. It is deployed in healthcare institutions in several countries and is recognised in the UK by NICE in a briefing to the NHS as a treatment for Hiatal hernia.

Sign in / Sign up

Export Citation Format

Share Document